Apr 06, 2020 / 12:00PM GMT
Operator
Greetings, and welcome to the Ruxolitinib Cream Phase III Data in Atopic Dermatitis webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to introduce Head of Investor Relations, Mike Booth. Please go ahead, Mike.
Michael Booth - Incyte Corporation - Divisional VP of IR & Corporate Social Responsibility
Thank you, Kevin. Good morning, and welcome to our conference call and webcast to discuss atopic dermatitis, the disease, the medical need and the Phase III ruxolitinib cream data presented yesterday at the Revolutionizing Atopic Dermatitis â Virtual Symposium. The slides used in today's webcast and those presented yesterday are available for download on the Investors section of incyte.com.
I'm joined on the call today by Hervé and by Jim Lee, our Head of Inflammation and Autoimmunity Development. And we're also delighted to welcome Dr. Larry Eichenfield from the University of San Diego. Dr. Eichenfield is a world-renowned expert in atopic dermatitis. He is a -- he is Professor of
Incyte Corp Corporate Call - Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis Transcript
Apr 06, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers